il2 cancer treatment | A systematic review of interleukin-2-based immu

Keyword	CPC	PCC	Volume	Score	Length of keyword
il2 cancer treatment	1.04	0.8	9485	19	20
il2	1.36	1	9323	88	3
cancer	0.13	1	2390	22	6
treatment	0.93	0.2	8478	45	9

Keyword	CPC	PCC	Volume	Score
il2 cancer treatment	0.11	0.4	6060	77
il-2 cancer treatment	1.38	0.7	2866	75
il2 cancer treatment side effects	1.92	0.1	1629	73
what is il 2 cancer treatment	1.66	0.8	5990	9
il 2 treatment for kidney cancer	0.24	1	8176	67
what is il-2 cancer treatment	1.89	0.5	5363	93
fda approved il-2 for cancer treatment	1.31	0.2	4377	10
interleukin-2 il-2 . cancer treatment	0.09	1	2790	55

Search Results related to il2 cancer treatment on Search Engine

A systematic review of interleukin-2-based immunotherapies in …
thelancet.com

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00104-4/fulltext

WEBMar 31, 2023 · High-dose interleukin-2 (IL-2) was the first approved immunotherapy for treatment of cancer. Apart from activating effector immune cells, IL-2 also stimulates regulatory T (Treg) cells, thus potentially limiting its efficacy as cancer treatment but offering opportunities to treat autoimmune diseases.

DA: 49 PA: 44 MOZ Rank: 33

‘IL-2Rα-biased’ IL-2 for cancer immunotherapy | Nature Cancer
nature.com

https://www.nature.com/articles/s43018-023-00613-z

WEBAug 7, 2023 · Nature Cancer - This study reveals the previously underappreciated roles of CD25 (IL-2 receptor subunit-α) in IL-2 biology and cancer immunotherapy and provides mechanistic insights into...

DA: 24 PA: 15 MOZ Rank: 72

A next-generation tumor-targeting IL-2 preferentially promotes …
nature.com

https://www.nature.com/articles/s41467-019-11782-w

WEBAug 28, 2019 · Nature Communications - Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a...

DA: 71 PA: 86 MOZ Rank: 89

IL-2: The First Effective Immunotherapy for Human Cancer - PMC
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293462/

WEBJun 6, 2014 · Go to: The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer.

DA: 97 PA: 39 MOZ Rank: 56

Role of IL-2 in cancer immunotherapy - PMC - National Center for
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938354/

WEBApr 25, 2016 · Conclusions. IL-2 plays a critical role in the activation of immune system that could be a useful way to eradicate cancer. As monotherapy, IL-2 has been demonstrated capable of mediating tumor regression and was approved for metastatic renal cell carcinoma and metastatic melanoma by FDA.

DA: 27 PA: 35 MOZ Rank: 11

Engineering IL-2 for immunotherapy of autoimmunity and cancer
nature.com

https://www.nature.com/articles/s41577-022-00680-w

WEBFeb 25, 2022 · IL-2 receptor (IL-2R) subunits CD25 (α-chain), CD122 (β-chain) and CD132 (common cytokine receptor γ-chain (γc)) each contain D1 and D2 domains of β-sheets. IL-2 mainly binds to D1 domains ...

DA: 64 PA: 72 MOZ Rank: 88

Interleukins in cancer: from biology to therapy - PMC
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173513/

WEBJun 3, 2021 · IL-2 was the first interleukin to be approved for cancer treatment, although its use entails major safety concerns 180. Recent advances focusing on modifying interleukins to reduce toxicity and increase the efficacy of treatment with recombinant and/or engineered interleukins might help to overcome this issue.

DA: 42 PA: 27 MOZ Rank: 1

Interleukin-2–based therapies in cancer - Science
science.org

https://www.science.org/doi/10.1126/scitranslmed.abo5409

WEBNov 9, 2022 · High-dose interleukin-2 (IL-2) (aldesleukin) was the first U.S. Food and Drug Administration (FDA)–approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) in 1992 and melanoma in 1998 and was approved as a combination treatment for neuroblastoma in 2015 ( Table 1) ( 1, 2 ).

DA: 9 PA: 5 MOZ Rank: 18

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2
biomedcentral.com

https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01826-7

WEBJul 29, 2023 · IL-2 has been shown to activate T cells, which can then target and kill cancer cells, while IL-2R is expressed on the surface of certain immune cells, such as natural killer (NK) cells, and can help to stimulate these cells to fight cancer [ 12, 13 ].

DA: 17 PA: 94 MOZ Rank: 95

Frontiers | Anti-cancer Therapies Employing IL-2 Cytokine Tumor
frontiersin.org

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02905/full

WEBDec 17, 2018 · Treatment with IL-2 has been associated with stable and curative regressions in patients with metastatic melanoma, renal cancer and advanced non-Hodgkin's lymphomas, representing the first effective immunotherapeutic agent ( 11 ).

DA: 78 PA: 66 MOZ Rank: 94